Aurobindo Pharma’s Eugia Unit‑III Granted OAI Classification by US FDA

Aurobindo Pharma’s Eugia Unit‑III has received OAI classification from the US FDA. Business Standard reported the regulatory decision. The OAI status applies to the Eugia Unit‑III facility. The US FDA announced the classification in its recent communication. The designation follows the agency’s standard review process. Aurobindo Pharma’s compliance with OAI criteria was confirmed. The news highlights the company’s adherence to regulatory standards. Observers will monitor how the classification impacts the firm’s operations.